sodium glucose cotransporter

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen, Michael Ingham

BMJ Open Diabetes Research and Care Nov 2019, 7 (1) e000704; DOI: 10.1136/bmjdrc-2019-000704
Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
Liang Xu, Naoto Nagata, Guanliang Chen, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Yuriko Sakai, Shuichi Kaneko, Tsuguhito Ota

BMJ Open Diabetes Research and Care Oct 2019, 7 (1) e000783; DOI: 10.1136/bmjdrc-2019-000783
Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
Gian Paolo Fadini, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, Emanuel Raschi

BMJ Open Diabetes Research and Care Oct 2019, 7 (1) e000725; DOI: 10.1136/bmjdrc-2019-000725
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
Stéphane Pintat, Peter Fenici, Niklas Hammar, Linong Ji, Kamlesh Khunti, Jesús Medina, Fengming Tang, Eric Wittbrodt, Filip Surmont

BMJ Open Diabetes Research and Care Mar 2019, 7 (1) e000627; DOI: 10.1136/bmjdrc-2018-000627

Main menu